Matches in SemOpenAlex for { <https://semopenalex.org/work/W3032863670> ?p ?o ?g. }
Showing items 1 to 70 of
70
with 100 items per page.
- W3032863670 endingPage "615" @default.
- W3032863670 startingPage "612" @default.
- W3032863670 abstract "ObjectiveTo analyze the efficacy and safety of Intra-arterial chemotherapy (IAC) as secondly treatment in children with retinoblastoma (RB).Methods42 eyes of 34 consecutive RB patients were enrolled in the study after intravenous chemotherapy (IVC), including 26 males and 8 females. The average age is 14.1 months. 21 cases were bilateral and 7 cases were unilateral. A total of 42 eyes of 34 patients were classified according to the International Intraocular Retinoblastoma Classification (IIRC) as group B(n=1, 2.4%), group C (n=3, 7.1%), group D (n=32, 76.2%), or group E (n=6, 14.3%). Tumor recurrence and tumor enlargement after IVC were 4 and 10 eyes respectively, accounting for 9.0% and 24.0% respectively. Sequential treatment after IVC followed by IAC were 28 eyes, accounting for 67.0%. All treatment eyes received IAC combined with laser, cryotherapy and other eye local treatment. The IAC regimen adopted the combination and alternation administration mode, by the combination of melphalan and carboplatin or the combination of melphalan and topotecan. According to the tumor changes after IAC decide whether IAC again. If tumors increased, vitreous or subretinal implants increased will be termination of IAC and enucleation. The mean follow-up time was (21.4±3.7) months after the last IAC treatment and (6.2±2.9) months after enucleation. Ocular preservation rate and complication were evaluated.ResultsThe average IAC procedures performed on 42 eyes were (4.0±0.9). An overall ocular preservation rate of 76.2% was observed during follow-up periods due to calcification or inactivation of tumors (32 eyes), including group B (n=1, 100%), group C (n=1, 33.3%), group D (n=27, 84.4%), group E (n=3, 50%). 10 eyes were enucleated. Among them, 2 eyes of the tumor did not shrink after IAC, tumor recurrence (n=3), vitreous hemorrhage (n=3), enophthalmos (n=1), vitreous disseminated (n=1). 34 cases of children, transient eyelid oedema were 18 cases, vitreous hemorrhage and bone marrow suppression (Ⅰ-Ⅳ) were 1, 22 casese respectively.ConclusionsIAC as secondly treatment is safe and effective for RB patients, however, there is still tumor recurrence. No serious ocular local and systemic complications were observed.Key words: Retinoblastoma/drug therapy; Chemotherapy, cancer, regional perfusion; Treatment outcome" @default.
- W3032863670 created "2020-06-05" @default.
- W3032863670 creator A5030374112 @default.
- W3032863670 creator A5033149181 @default.
- W3032863670 creator A5038158677 @default.
- W3032863670 creator A5063566720 @default.
- W3032863670 creator A5067750232 @default.
- W3032863670 creator A5068899332 @default.
- W3032863670 date "2017-11-25" @default.
- W3032863670 modified "2023-09-24" @default.
- W3032863670 title "Intra-arterial chemotherapy as secondly therapy for retinoblastoma" @default.
- W3032863670 doi "https://doi.org/10.3760/cma.j.issn.1005-1015.2017.06.014" @default.
- W3032863670 hasPublicationYear "2017" @default.
- W3032863670 type Work @default.
- W3032863670 sameAs 3032863670 @default.
- W3032863670 citedByCount "0" @default.
- W3032863670 crossrefType "journal-article" @default.
- W3032863670 hasAuthorship W3032863670A5030374112 @default.
- W3032863670 hasAuthorship W3032863670A5033149181 @default.
- W3032863670 hasAuthorship W3032863670A5038158677 @default.
- W3032863670 hasAuthorship W3032863670A5063566720 @default.
- W3032863670 hasAuthorship W3032863670A5067750232 @default.
- W3032863670 hasAuthorship W3032863670A5068899332 @default.
- W3032863670 hasConcept C104317684 @default.
- W3032863670 hasConcept C118487528 @default.
- W3032863670 hasConcept C141071460 @default.
- W3032863670 hasConcept C185592680 @default.
- W3032863670 hasConcept C188261085 @default.
- W3032863670 hasConcept C2776577112 @default.
- W3032863670 hasConcept C2776694085 @default.
- W3032863670 hasConcept C2777104736 @default.
- W3032863670 hasConcept C2778239845 @default.
- W3032863670 hasConcept C2778257484 @default.
- W3032863670 hasConcept C2778684742 @default.
- W3032863670 hasConcept C2780149145 @default.
- W3032863670 hasConcept C2781209748 @default.
- W3032863670 hasConcept C2781242345 @default.
- W3032863670 hasConcept C2781451048 @default.
- W3032863670 hasConcept C55493867 @default.
- W3032863670 hasConcept C71924100 @default.
- W3032863670 hasConcept C81182388 @default.
- W3032863670 hasConceptScore W3032863670C104317684 @default.
- W3032863670 hasConceptScore W3032863670C118487528 @default.
- W3032863670 hasConceptScore W3032863670C141071460 @default.
- W3032863670 hasConceptScore W3032863670C185592680 @default.
- W3032863670 hasConceptScore W3032863670C188261085 @default.
- W3032863670 hasConceptScore W3032863670C2776577112 @default.
- W3032863670 hasConceptScore W3032863670C2776694085 @default.
- W3032863670 hasConceptScore W3032863670C2777104736 @default.
- W3032863670 hasConceptScore W3032863670C2778239845 @default.
- W3032863670 hasConceptScore W3032863670C2778257484 @default.
- W3032863670 hasConceptScore W3032863670C2778684742 @default.
- W3032863670 hasConceptScore W3032863670C2780149145 @default.
- W3032863670 hasConceptScore W3032863670C2781209748 @default.
- W3032863670 hasConceptScore W3032863670C2781242345 @default.
- W3032863670 hasConceptScore W3032863670C2781451048 @default.
- W3032863670 hasConceptScore W3032863670C55493867 @default.
- W3032863670 hasConceptScore W3032863670C71924100 @default.
- W3032863670 hasConceptScore W3032863670C81182388 @default.
- W3032863670 hasIssue "6" @default.
- W3032863670 hasLocation W30328636701 @default.
- W3032863670 hasOpenAccess W3032863670 @default.
- W3032863670 hasPrimaryLocation W30328636701 @default.
- W3032863670 hasVolume "33" @default.
- W3032863670 isParatext "false" @default.
- W3032863670 isRetracted "false" @default.
- W3032863670 magId "3032863670" @default.
- W3032863670 workType "article" @default.